NCT01200381

Brief Summary

It's the aim of this study to analyze the benefit of personal patient / physician contacts in heart failure patients with remotely monitored implanted cardioverter defibrillators (ICD) or ICD with cardiac resynchronization therapy (CRT-D). The personal follow up (in clinic or phone calls) will be compared to completely automatic remote follow ups. All patients will receive remote monitoring for automatic daily alarm checks and will undergo in clinic follow ups in 12 months intervals

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P50-P75 for not_applicable heart-failure

Timeline
Completed

Started Feb 2010

Longer than P75 for not_applicable heart-failure

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 10, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 13, 2010

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
Last Updated

February 4, 2019

Status Verified

February 1, 2019

Enrollment Period

4.4 years

First QC Date

September 10, 2010

Last Update Submit

February 1, 2019

Conditions

Keywords

ICDCRTDRemote careRemote monitoringHeart failure

Outcome Measures

Primary Outcomes (1)

  • Amount of patients with worsened outcome in reference to Packer's "Heart Failure Clinical Composite Response"

    12 months (between 1 and 13 months post implant)

Secondary Outcomes (7)

  • Mortality

    12 months (between 1 and 13 months post implant)

  • Heart failure hospitalizations

    12 months (between 1 and 13 months post implant)

  • Cardiovascular events

    12 months (between 1 and 13 months post implant)

  • Number of additional, unscheduled follow ups

    12 months (between 1 and 13 months post implant)

  • Number of follow ups with relevant findings

    12 months (between 1 and 13 months post implant)

  • +2 more secondary outcomes

Study Arms (3)

Group A

ACTIVE COMPARATOR

Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)

Other: Quarterly remote follow ups and remote monitoring

Group B1

ACTIVE COMPARATOR

Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)

Other: Quarterly remote follow ups + additional phone calls and remote monitoring

Group B2

ACTIVE COMPARATOR

Personal ICD/CRTD follow up (Quarterly visits)

Other: Quarterly in clinic follow ups and remote monitoring

Interventions

Quarterly remote follow ups and remote monitoring

Group A

Quarterly remote follow ups + additional phone calls and remote monitoring

Group B1

Quarterly in clinic follow ups and remote monitoring

Group B2

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indication for implantation (new, boxchange, upgrade) of ICD/ CRT-D
  • Written informed consent
  • Ejection Fraction \<= 35%
  • New York Heart Association (NYHA) Class I-III
  • Age \>=18 and \<=80 years
  • In patient's home environment sufficient infrastructure (analog phone line or sufficient strength of GSM (Global System for Mobile communication) mobile phone network) for running a Merlin@home transmitter is available

You may not qualify if:

  • Arterio ventricular (AV) Block III / AV Block II Type Mobitz
  • Severe renal insufficiency
  • Coronary angiology intervention within previous 3 months
  • Myocardial infarction within previous month
  • Life expectancy \< 1 year
  • Expected poor data quality / compliance
  • Pregnancy
  • Patient is already participating to another study with active therapy arm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald

Bad Friedrichshall, 74177, Germany

Location

Asklepios Klinik Bad Oldesloe

Bad Oldesloe, 23843, Germany

Location

Segeberger Kliniken GmbH

Bad Segeberg, 23795, Germany

Location

Evangelisches Krankenhaus Bielefeld gGmbH

Bielefeld, 33617, Germany

Location

Evangelisches Krankenhaus Kalk

Cologne, 51103, Germany

Location

Universitätsklinikum Essen (AöR)

Essen, 45122, Germany

Location

Herzkatheterlabor der Kardiologischen Praxis am Krankenhaus Neu-Bethlehem gGmbH

Göttingen, 37073, Germany

Location

Asklepios Klinik St. Georg

Hamburg, 20099, Germany

Location

Asklepios Klinik Barmbek

Hamburg, 22307, Germany

Location

Klinikum Ingolstadt GmbH

Ingolstadt, 85049, Germany

Location

Kardiologische Praxis - Partnergesellschaft

Ludwigsburg, 71634, Germany

Location

Städtisches Klinikum Lüneburg gGmbH

Lüneburg, 21339, Germany

Location

Marienhaus Klinikum St. Elisabeth-Krankenhaus

Neuwied, 56564, Germany

Location

Praxis Dr. med. Balbach / Ruppert

Nürtingen, 72622, Germany

Location

Kardiologische Gemeinschaftspraxis am Park Sanssouci

Potsdam, 14471, Germany

Location

Klinikum Sindelfingen-Böblingen gGmbH

Sindelfingen, 71065, Germany

Location

Marienhospital Stuttgart

Stuttgart, 70199, Germany

Location

Related Publications (1)

  • Hansen C, Loges C, Seidl K, Eberhardt F, Troster H, Petrov K, Gronefeld G, Bramlage P, Birkenhauer F, Weiss C. INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients with Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact). BMC Cardiovasc Disord. 2018 Jun 28;18(1):131. doi: 10.1186/s12872-018-0864-7.

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Christian Weiss, Prof. Dr. med.

    Städtisches Klinikum Lüneburg gGmbH

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2010

First Posted

September 13, 2010

Study Start

February 1, 2010

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

February 4, 2019

Record last verified: 2019-02

Locations